Drug development of immunotherapy targeting NSCLC with a driver mutation involving ALK and advanced neuroendocrine tumors (NETs) including pulmonary LCNEC are currently ongoing [18,19]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.